The trend of outsourcing is increasing the thrust of contract development and manufacturing organizations (CDMOs) into the spotlight. There is a push towards engaging the services of CDMOs by emerging biotechnology groups which don’t have the resources to do development or manufacturing in-house; and, by larger biopharmaceutical companies which are facing capacity constraints and looking to quickly increase their current capacity. To meet these changing demands, it is critical for CDMOs to find ways to scale, and scale quickly, within their current footprint. At Thermo Fisher Scientific, we are able to offer a range of solutions from supporting CDMOs to serving as a CDMO.
Interested in learning more? Watch our webinar titled, "Accelerating Progress: key considerations for CDMOs to maximize productivity and scalability."
Read about the Hyperforma DynaDrive 5,000 L bioreactor, its operational and economic implications, and how the biopharma industry might change with the introduction of this system.
This whitepaper highlights features and benefits of the DynaDrive SUB platform and explains how any new or existing facility can leverage the platform to achieve expected development and manufacturing objectives.
The TCO of production chemicals and direct materials used in bioproduction can vary. While product price is an important and readily visible cost, hidden costs—like supplier and order management, on-time-in-full (OTIF), warehouse space requirements, safety stock inventory, among others—can have significant impacts on the overall cost of production chemicals.
The industry is facing supply shortage, and companies must mitigate supply challenges to ensure they are able to continue their critical work. Listen to a customer’s perspective on the significance of working with a reliable partner for redundancy of supply, timing, and quality.
For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.